IRQ Articles

SIR Foundation research forum 

10-17-2017 17:02

Interview with Ziv J Haskal, MD, FSIRnRSQvaUhRsidBzdkyI3v_Twitter_Bird2.png

Fall 2017

Ziv HaskalThe Journal of Vascular and Interventional Radiology (JVIR) is pleased to announce the launch of the JVIR Trials submission form (bit.ly/2gc0Pom). Once data is collected, JVIR Trials will function as a voluntary registry of active prospective clinical trials in interventional radiology. This unique repository will provide an invaluable opportunity for researchers to increase visibility, awareness and access to interventional science.

IRQ spoke with JVIR Editor-in-chief Ziv J Haskal, MD, FSIR, about his vision for this exciting new platform.

Why do you feel an online collection of IR trials is so important?

Our specialty now consistently undertakes and reports prospective higher level of evidence research. And yet, the majority of this research is unregistered or effectively undiscoverable on national websites. Try, for example, to easily find all the interventional oncology trials on clinicaltrials.gov. Prepare for frustration.

What is your primary goal with JVIR Trials?

As editor-in-chief, one of my ongoing goals has always been to improve the quality of our published research, both in form and substance. This means encouraging neutral and detailed scientific reporting that allows our research to stand with all other top journals, now and in the future, and promoting prospective hypothesis-driven clinical research.

How will JVIR Trials help meet that need?

The breadth of IR research is vast but, at present, there is no central repository where both readers and researchers can see the specific IR-related trials underway, be they registered trials or single-site, IRB-approved, smaller-scale investigations. National and international registered trial websites are essential, but they are neither comprehensive, nor are they sufficiently user friendly for finding IR research.

JVIR Trials submission formSo JVIR Trials will be limited to research related to IR. Will there be other restrictions?

The website will house brief descriptions of all current prospective IR studies, whether they are industry sponsored, individual operator, multicentric or nationally sponsored. No prospective study is too small to be listed.

How else will it benefit the research community?

JVIR Trials will provide interventional radiologists, patients and other specialty clinicians a visible and public warehouse for all prospective IR-related research. The site will house trials registered on other sites, commercially sponsored studies, and investigator-sponsored research. Importantly, it will also accept any prospective IRB/ethics board-approved trial, including small phase 1 studies. I want to feature all IR prospective research—to move us from retrospective reports to methodical protocol driven efforts—even at the earliest phase I stages. No other resource does this.

JVIR Trials will also provide a networking opportunity for investigators to potentially band their listed small early studies into large multicenter phase I/II studies. It will allow patients to find the innovative clinical trials they may be seeking for themselves or their families. It will make publicly and abundantly clear what important and interesting research is undertaken within our specialty.

How might JVIR Trials benefit SIR’s corporate partners?

High-quality multicenter validation of therapies and technologies are expensive. Good questions will always involve partnerships with corporations. JVIR Trials welcomes these studies and hopes to highlight IR investigators and potentially boost enrollments. This is a win–win.

Flash forward five years. How will you know if the resource has succeeded? How will you know if it hasn’t met your expectations?

In my vision, ideally JVIR Trials will have become a lead resource for researchers and patients, a tool routinely used by practitioners seeking updates on ongoing research, IR and endovascular scientists considering their own new trials, and corporations looking to boost their studies toward completion. Prospective protocol driven research may require 3–7 times more effort than retrospective record review. But it is the ethical approach and the measure of meaningful and durable impact and contribution. We need to embrace this expectation and culture by helping celebrate and model this for current and future IR clinician-scientists.

Is there anything else you’d like to tell IRQ readers?

I hope the transparency brought by this listing will serve researchers, encourage more prospective projects and rightfully instill pride in all of us for the diversity of important work conducted in our field.

Connect with SIR

AD: Sirtex